The Screening Paradox
Preventive screening feels intuitively beneficial — catch disease early, treat it easily. Yet the evidence reveals a more nuanced picture. Effective screening requires that early detection actually improves outcomes and that the test does more good than harm. Some widely marketed screenings deliver false positives, overdiagnosis, and cascade testing that harms healthy people. The US Preventive Services Task Force (USPSTF) rigorously evaluates this balance, and its recommendations — graded A through D — represent the most reliable guide to which tests are worth doing.
High-Value Screenings
Several screenings have strong evidence for reducing mortality. Colorectal cancer screening starting at age 45 (via colonoscopy, stool DNA, or FIT testing) prevents cancer by removing precancerous polyps. Cervical cancer screening with Pap and HPV testing has dramatically reduced cervical cancer deaths. Blood pressure and lipid screening identify treatable cardiovascular risk. Mammography reduces breast cancer mortality in women 50-74, with individualized decisions for those 40-49. Lung cancer screening with low-dose CT benefits long-term heavy smokers.
Screenings to Approach Critically
Other tests warrant caution. PSA screening for prostate cancer carries real risks of overdiagnosis and overtreatment, warranting shared decision-making rather than routine testing. Whole-body MRI scans and many direct-to-consumer blood panels marketed to healthy people lack outcome evidence and generate incidental findings that trigger anxiety and unnecessary procedures. The guiding principle: screening should be targeted to individual risk and grounded in evidence, not maximized. Facilities delivering preventive care can source diagnostic equipment and lab supplies through our catalog.
